Treace Medical Concepts, Inc. (TMCI)
After hours:
| Previous close | 11.53 |
| Open | 11.63 |
| Bid | 11.37 x 100 |
| Ask | 11.42 x 100 |
| Day's range | 11.27 - 11.76 |
| 52-week range | 5.27 - 27.70 |
| Volume | |
| Avg. volume | 415,875 |
| Market cap | 706.07M |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.81 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.86 |
GlobeNewswireTreace to Present at Bank of America Health Care Conference
Wednesday, May 15, 2024, at 2:20 pm Pacific TimePONTE VEDRA, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fires
GlobeNewswireTreace Announces First Annual National Bunion Day
Focus on Foot Health Issue Affecting Millions of People Includes Outreach and Education Efforts to Build Awareness, Reduce Stigma and Correct Misconceptions About This Common Bone DeformityPONTE VEDRA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Pro
- GlobeNewswire
Treace to Report First Quarter 2024 Financial Results
Company to Host Conference Call on Tuesday, May 7, 2024 at 4:30 pm ETPONTE VEDRA, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter of 2024 after the close of trading
